Formosa Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020
May 13, 2020 at 09:02 pm
Share
Formosa Laboratories, Inc. announced earnings results for the first quarter ended March 31, 2020. For the first quarter, the company announced sales was TWD 662.643 million compared to TWD 654.322 million a year ago. Operating loss was TWD 48.415 million compared to TWD 97.199 million a year ago. Net loss was TWD 101.880 million compared to net income of TWD 32.141 million a year ago. Basic loss per share was TWD 1.03 compared to basic earnings per share of TWD 0.32 a year ago. Diluted loss per share was TWD 1.03 compared to diluted earnings per share of TWD 0.31 a year ago.
Formosa Laboratories, Inc. is a Taiwan-based company principally engaged in the development, production and distribution of ultraviolet (UV)-proof active ingredients, bulk pharmaceutical chemicals, antibody drug conjugates, as well as the provision of customized services. The Company primarily provides UV-proof active ingredients series products, vitamin D derivative series products, anti-inflammatory analgesic series products, steroid, anti-cancer drugs, cholesterol phosphate binding agents, nuclear magnetic resonance (NMR) reagents, respiratory disease drugs, central nervous system drugs, immune system regulators and weight loss drugs, as well as customized research and development and original equipment manufacturing (OEM) services. The Company distributes its products to Europe, the Americas, Asia and other markets.